The Zhitong Finance App learned that Shenwei Pharmaceutical (02877) rose by nearly 7%, reaching a high of HK$8.97 since August 2023. As of press release, it rose 6.7% to HK$8.92, with a turnover of HK$4.923 million.
According to the news, Hang Seng Index Limited recently announced the results of the Hang Seng Index series quarterly review for the year ended 31 December 2023. Among them, Shenwei Pharmaceutical has been included in a total of 5 indices, including the Hang Seng Composite Index, etc. The relevant changes will take effect on March 4, 2024. CCB International previously stated that benefiting from the general increase in medical product sales in FY2023, the company's total revenue for the fourth quarter is expected to increase 10% quarterly, raising its profit forecast for the 2023/24 fiscal year by 8%/6%.